Procore signs multi-year strategic collaboration agreement with AWS
Rui Avelar, an executive at Evolus, Inc. (NASDAQ:EOLS), a $840 million market cap company that has seen impressive 32% revenue growth over the last twelve months, recently sold a significant portion of the company’s stock. According to a recent SEC filing, Avelar sold 27,904 shares of Evolus common stock on March 18, 2025. The shares were sold at prices ranging from $13.174 to $13.256, with a weighted average sale price of $13.255, totaling approximately $369,867.
This transaction was conducted under a Rule 10b5-1 trading plan, a prearranged plan that allows insiders to sell stock without violating insider trading laws. The sale was necessary to cover tax withholding obligations related to the vesting of certain Restricted Stock Units.
Following this transaction, Avelar holds 362,467 shares of Evolus stock directly.
In other recent news, Evolus reported its fourth-quarter 2024 financial results, revealing a revenue of $79 million, which exceeded expectations of $76.96 million, despite missing earnings per share (EPS) estimates with a reported EPS of -$0.11 versus the forecasted $0.02. The company achieved full-year revenues of $266.3 million, marking a 32% increase year-over-year, and confirmed its guidance for 2025, projecting revenues between $345 million and $355 million. This growth is expected to be supported by the newly launched Evolysse products, anticipated to contribute 8-10% of total 2025 revenue. Analysts from Stifel and H.C. Wainwright maintained their Buy ratings on Evolus, with price targets set at $25 and $27, respectively, citing confidence in the company’s financial trajectory and market performance. Evolus also achieved profitability ahead of schedule, with a positive non-GAAP operating income of $0.3 million for 2024. The company experienced a significant increase in active accounts and record enrollment in its loyalty programs, surpassing 1.1 million participants. Looking forward, Evolus aims for operating profitability for the full fiscal year 2025, driven by the early approval of new products and continued market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.